BCL2L1 and cancer: Mechanistically, increased NOXA expression, observed upon antimitotic treatment [46,50,51], EMT [33] or ER stress [52], is expected to modify dependence of cancer cells on BCL-2 family proteins, shifting the burden to support viability from MCL-1 (buffered by NOXA) to BCL-xL exclusively.